What Is Outplacement and How Does It Work? DACH Pharma Guide

What is outplacement, and how does it work?

Outplacement is career transition support that an employer buys and pays for when it separates from an employee. The employer is the paying client. The employee is the candidate and pays nothing. That funding line separates it from career coaching a person buys privately. In Germany it is agreed inside an Aufhebungsvertrag, a mutual termination agreement, or inside a Sozialplan. A mandate runs from assessment through positioning, documents, market access, applications, offer negotiation and onboarding. No German statute obliges an employer to provide it. Tax law favours it: under § 3 Nr. 19 EStG the employer's payment is tax free for the employee.

The German outplacement market billed 98 million euro in 2024, against 78 million in 2023, and its roughly 60 firms worked with about 11,000 candidates. Those BDU market study figures, published 28 May 2025, also describe who sits in the chair: average gross annual income 112,000 euro, 65 per cent of candidates aged 50 to 59.

I have recruited in pharma for 16 years, eight at Bayer and five with large CROs. I have hired people who came out of an outplacement programme, and read CVs from people whose programme produced a folder of certificates and no employment contract. My test is narrow. Did the candidate sign a contract, and how many months did it take.

What is outplacement, who pays for it, and who gets it?

Outplacement is a service an employer commissions to help a departing employee find the next job. Career coaching is bought by the individual with private money and has no connection to any employer decision. Same activities in places, different accountability, and the candidate needs to know what gets reported back to the payer.

Nobody is owed it. Who gets it comes out of a negotiation, and the offer lands in one of two documents: an individual Aufhebungsvertrag, the mutual termination agreement that ends employment without a dismissal, or a Sozialplan, the works agreement under § 112 BetrVG that compensates or softens the economic disadvantages of a Betriebsänderung. Bayer's announcement of 10 July 2025 on the Frankfurt withdrawal is the second route: the agreed package covers relocation, severance and, in Bayer's wording, support in finding a job outside Bayer.

Employers pay for unsentimental reasons. A signed Aufhebungsvertrag closes the file, while a contested dismissal produces a Kündigungsschutzklage, months of continued salary and an uncertain settlement. Outplacement raises the perceived value of a package without raising the cash figure, and the people who stay watch how the leavers get treated. On price, what is documented is the aggregate: 98 million euro across about 11,000 candidates in 2024, roughly 8,900 euro per head across all formats.

What is the difference between Einzel-Outplacement, Gruppen-Outplacement and a Transfergesellschaft?

Einzel-Outplacement gives one candidate a named consultant. Fixed-term individual mandates were 39 per cent of 2024 engagements, open-ended ones 11 per cent. Gruppen-Outplacement, sold as Projekt-Outplacement, handles a cohort from one restructuring and was half of all engagements: shared workshops, individual sessions rationed.

A Transfergesellschaft is a different instrument. It is a temporary employer, and the distinction matters in a negotiation. The employee signs a dreiseitiger Vertrag between old employer, employee and transfer company, ending the old employment relationship and starting a fixed-term one inside a betriebsorganisatorisch eigenständige Einheit, an organisationally separate unit known as a beE. Transferkurzarbeitergeld under § 111 SGB III runs for a maximum of twelve months, no extension. The rate follows § 105 SGB III: 67 per cent of the Nettoentgeltdifferenz with a qualifying dependent child, 60 per cent otherwise. Employers usually top that up, and the top-up plus social contributions are the Remanenzkosten. Entry requires a profiling measure and prior consultation with the Agentur für Arbeit.

While the employee is still employed, § 110 SGB III funds Transfermaßnahmen, and the Fachliche Weisungen name Bewerbungstraining and Outplacement as fundable measures. The subsidy is 50 per cent of necessary and appropriate costs, capped at 2,500 euro per employee. Four conditions apply: prior advice from the Agentur für Arbeit, delivery by a third party, a labour market integration purpose, and secured delivery. Funding is excluded where the measure prepares the employee for another job in the same company or group.

What happens in an outplacement mandate, phase by phase?

Standortbestimmung comes first, an assessment of where the candidate stands. Two to four sessions, covering the verifiable track record, how the separation will be explained, income expectations and geographic limits. Short phase, hard work, because fifteen years in one company distorts a person's picture of their own market value.

Positioning and documents follow. The candidate picks two or three role types and everything downstream is written for those: CV, cover letter, LinkedIn, XING, reference letters. In pharma this is where machine screening bites, because applicant tracking systems filter on exact strings such as GxP, GCP, ICH E6(R3), EU GMP Annex 1 and the German role titles, which I covered in how to beat applicant tracking systems in pharma. Two to three weeks of genuine work.

Market access separates the providers. It means a named target list of employers, the hiring managers behind the roles, and direct contact. The BDU study attributes 26 per cent of placements to advertised positions and 24 per cent to the consultant's own network. A provider that cannot describe its network in your segment has a database subscription, not market access; the direct method is in reverse recruitment for pharma professionals. Then months of applications, then offer negotiation, where freshly redundant candidates take the first number offered. Mechanics in salary negotiation in pharma.

How long does an outplacement mandate run, and what does "until placement" mean?

Fixed-term mandates in Germany commonly run three, six or twelve months. Open-ended mandates, marketed as bis zur Vermittlung, until placement, were 11 per cent of engagements in the BDU 2024 data. The same study reports 93 per cent of candidates in a new job within twelve months at most and 40 per cent within six months or less, with 79 per cent going into employment and 6 per cent into self-employment.

Bis zur Vermittlung is a contract term. Read it as one. Ask what counts as Vermittlung: a signed permanent contract is one definition, a freelance assignment or a fixed-term bridge role is another, and if those count as fulfilment the mandate can close months before the candidate reaches anything stable. Ask what happens if the candidate declines an offer, and whether a hard outer limit sits in a side clause.

Then ask what the mandate contains after month six. Programmes front-load: contact thins to a monthly call once documents and workshops are done, precisely when a narrow specialism needs a consultant on the phone. Get the session count for the second half in writing.

Which rules touch outplacement in Germany, Austria and Switzerland?

No German statute creates an entitlement to outplacement; law only sets the frame. § 111 BetrVG obliges employers with more than twenty employees entitled to vote to inform and consult the works council on a Betriebsänderung, which covers closure, relocation, mergers, reorganisation and substantially new work methods. § 112 BetrVG governs the Interessenausgleich and the Sozialplan, which has the effect of a works agreement and can be imposed by the Einigungsstelle if the parties fail to agree.

Under § 3 Nr. 19 EStG, consulting services provided by the employer, or by a third party at the employer's instigation, for the employee's berufliche Neuorientierung on termination of employment are tax free, provided they do not have a predominantly rewarding character. That wording came in with the Jahressteuergesetz 2020 of 21 December 2020; before it, OFD Nordrhein-Westfalen guidance of 4 August 2020 treated outplacement as taxable wages. Ten thousand euro of outplacement reaches the employee untaxed. Ten thousand euro added to the Abfindung does not.

The Abfindung is taxable. The Fünftelregelung under § 34 EStG survives, but since 1 January 2025 the employer no longer applies it in payroll under the Wachstumschancengesetz, so the employee claims it in a tax return. Two further provisions matter: § 1a KSchG sets statutory severance at 0.5 monthly earnings per year of employment, periods over six months rounded up, and § 159 SGB III imposes a twelve-week Sperrzeit on unemployment benefit where the employee gave up the job without an important reason.

Austria and Switzerland run different machinery. The Austrian instrument is the Arbeitsstiftung or Outplacementstiftung, recognised under § 18 Abs. 5 to 9 AlVG with living cost support under § 35 AMSG, and participation can extend unemployment benefit for up to 156 weeks. In Switzerland, Art. 335i OR obliges employers with at least 250 staff who intend to dismiss at least 30 within 30 days to negotiate a Sozialplan.

What makes outplacement in the DACH pharma market different?

The volume comes from restructuring. Large pharmaceutical companies with at least 20 billion dollars of 2025 revenue cut more than 22,000 jobs that year, against a patent cliff of roughly 300 billion dollars in prescription revenue losing protection between 2025 and 2030. Bayer went from about 100,000 employees to roughly 88,000 across 2024 and 2025. In DACH: Bayer withdraws Crop Science from Frankfurt by 2028 while guaranteeing its other German sites to 2030, Novartis closes the Wehr plant by end 2028 with 220 jobs affected, and Takeda cut 280 roles in Opfikon.

Sector employment tells a different story. The vfa reported on 27 October 2025 that German pharmaceutical employment was still growing, up 0.2 per cent in 2025 with 1.1 per cent forecast for 2026. BPI data counts 671 pharmaceutical companies in Germany for 2023 and 133,376 employees in 2024, and IW research for the vfa found 176,000 unfilled positions across pharma-relevant occupations in 2023, mostly in production and laboratory work. The cuts land on commercial headquarters functions. Someone leaving a German site is leaving a job category one company stopped funding. The industry itself is growing.

The niches change the arithmetic. Regulatory Affairs, Pharmakovigilanz, Medical Affairs, Clinical Operations and QA/GMP are not mass occupations, and some are capped by regulation. Article 104(3)(a) of Directive 2001/83/EC requires each marketing authorisation holder to have permanently and continuously at its disposal one appropriately qualified person responsible for pharmacovigilance, resident and operating in the Union. One QPPV per holder. Across 671 German companies, the realistic pool for a senior pharmacovigilance lead within reach of Frankfurt or Basel is a two-digit number, and the other statutory roles in German pharma are just as thin.

That is why time to placement behaves differently. A mass occupation lets volume compensate for a low response rate; a niche has none, so the search starts with people rather than postings, and processes run longer because a QA or Regulatory hire gets evidenced against GMP or GxP requirements. The silences in between are normal and corrosive, which I dealt with in the piece on ghosting in pharma recruiting.

How do you tell a good outplacement provider from a bad one, and what can it not do?

Ask questions that force a specific answer. A generalist replies in adjectives. A specialist replies with names and dates.

How many candidates from my function and industry did you place in the last twelve months, and where did they go?
Who is my consultant, and will they still be my consultant in month eight?
How many contact hours in months one to three, and how many in months four to twelve?
What gets reported to my former employer, and do I see it first?
What does the contract define as Vermittlung, and what ends the mandate?
Do you approach named employers for me, or forward me postings?

An HR lead buying for a group should add two: which named consultants will actually deliver, and whether the provider holds the Trägerzulassung needed for funding under § 110 SGB III, since the Fachliche Weisungen require an approved third party. If a Transfergesellschaft is on the table, have the Remanenzkosten modelled before the works council sees a number. The warning signs are specific: no named consultant before signature, a fee paid in full at kick-off, clauses requiring the candidate to report progress to former management, and a scope written as a session count with nothing defining the sessions. Guarantees of placement are the clearest signal, because nobody can honour one.

Outplacement is not job placement. The provider does not employ the candidate and owes them no job. It does not create vacancies that do not exist, repair a track record with unexplained gaps, or shorten a hiring process a company has decided will take five months. It cannot fix a candidate who will not relocate or accept a title change, and it is not legal advice. What it does is compress the time between separation and signature and give a senior person a market strategy instead of a job board habit, which I set out in the pharma job search strategy guide.

Frequently asked questions

Does my employer have to offer me outplacement?

No. No German statute creates an individual right to it. It comes from contract, either an Aufhebungsvertrag you negotiate or a Sozialplan agreed under § 112 BetrVG. Where a Sozialplan grants it, the works agreement sets out who qualifies. In an individual negotiation it is a bargaining item like the Abfindung and the reference letter.

Do I pay tax on outplacement my employer buys for me?

No, provided it falls under § 3 Nr. 19 EStG, which since the Jahressteuergesetz 2020 covers employer consulting for berufliche Neuorientierung on termination, as long as the benefit has no predominantly rewarding character. That argues for outplacement over the cash equivalent: an Abfindung is taxable, and since 1 January 2025 the employer no longer applies the Fünftelregelung in payroll.

Is a Transfergesellschaft better than an Abfindung?

They answer different problems. A Transfergesellschaft buys time on a fixed-term contract with Transferkurzarbeitergeld under § 111 SGB III for at most twelve months, which suits someone who needs retraining or a long search. The Abfindung plus a direct search suits someone with a strong market. Entering the transfer company ends the old employment relationship, so any pending Kündigungsschutzklage position goes with it.

How long should I expect the search to take in pharma?

The BDU 2024 data across all industries shows 93 per cent placed within twelve months and 40 per cent within six months or less. Treat the upper half as the planning assumption for a specialised DACH pharma role, where the regional employer pool is small. Plan cash for twelve months.

Sources

Facing a separation in pharma, or buying outplacement for a team?

Book a free getting-to-know call. I will tell you what your record is worth in the current DACH market, which employers in your niche are actually hiring, and whether the package on your table is worth signing. The programme itself is described under outplacement for pharma professionals.

Book a Free Getting to Know Call